Acutaas Chemicals Ltd · NSE:ACUTAAS
Acutaas Chemicals — Ami Organics — Q2 FY25 Earnings Presentation
41 slides from Acutaas Chemicals's earnings presentation, Oct 29, 2024
Slide 1: Exchange cover letter for investor presentation
Afi Ami Organics Limited CIN. : L241OOGJ2007PL00510§3 Registered Office :- Plot No. 440/4, 5 & 6, Road No. 82/A, G.L.D.C. Sachin, Surat - 394230, Dist. Surat, Gujarat, India. October 29, 2024 To, To, The Listing Department, The Listing Department BSE LIMITED, National Stock Exchange of India Limited,
Slide 2: Investor Presentation October 2024
Investor Presentation O C TO B E R 2 0 2 4 BSE : 543349 | NSE : AMIORG | www.amiorganics.com 1
Slide 3: Table of Contents
Table of Contents 01 02 03 Q2 & H1FY25 Results Company Overview Advanced Pharma Intermediate 04 05 Specialty Chemicals Working towards better tomorrow 2
Slide 4: 1. Q2 & H1FY25 Results
1. Q2 & H1FY25 Results Management Commentary Q2FY25 Earnings Highlights Q2FY25 Business Highlights Q2FY25 Financial Performance – Key Metrics H1FY25 Financial Performance – Key Metrics Q2 & H1FY25 Financial Performance – P&L Statement Financial Performance over the years – Key Metrics
Slide 5: Management Commentary
Management Commentary "Despite ongoing challenges in the global chemical industry, I am pleased to report stellar year-over-year growth of 43.2% in Q2FY25, driven by exceptional performance in our Pharmaceutical Intermediates and Specialty Chemicals businesses. Our key products maintained growth mom
Slide 6: Q2FY25 Earnings & Business Highlights
Q2FY25 Earnings & Business Highlights Revenue from operations for Q2FY25 grew by 43.2% YoY to Rs. 2,467 mn The gross margin for the quarter improved to 43.4% up 239 bps YoY and 136 bps QoQ EBITDA for the quarter came at Rs. 489 mn up 97.2% YoY compared to Rs. 248 mn in Q2FY24. EBITDA margin
Slide 7: Q2FY25 Financial Performance – Key Metrics
Q2FY25 Financial Performance – Key Metrics Revenue from Operations (Rs Mn) YoY Growth 53.1% 7.6% 43.2% Q2FY24 Q2FY25 2,467 2,061 1,724 1,346 378 407 Advance Intermediates Specialty Chemicals Total EBITDA & EBITDA Margin PAT (Rs Mn) (Rs Mn) 15.2% 19.8% 14.4% 8.5% 248 489 147 376 Q2FY24 Q2FY25 Q2FY24
Slide 8: H1FY25 Financial Performance – Key Metrics
H1FY25 Financial Performance – Key Metrics Revenue from Operations (Rs Mn) YoY Growth 36.5% 8.2% 29.8% H1FY24 H1FY25 4,234 3,406 3,261 2,496 765 828 Advance Intermediates Specialty Chemicals Total EBITDA & EBITDA Margin PAT (Rs Mn) (Rs Mn) 18.5% 12.3% 18.0% 11.3% 588 784 370 523 H1FY24 H2FY25 H1FY24
Slide 9: Q2 & H1FY25 Financial Performance – P&L Statement
Q2 & H1FY25 Financial Performance – P&L Statement Particulars (Rs. Mn) Q2FY25 Q2FY24 YoY Q1FY25 QoQ H1FY25 H1FY24 YoY Revenue from Operations 2,467 1,724 43.2% 1,767 39.7% 4,234 3,261 29.8% COGS 1,396 1,016 1,023 2,419 1,817 Gross Profit 1,072 708 51.5% 743 44.2% 1,815 1,444 25.7% Gross Margin 43.4%
Slide 10: Financial Performance over the years – Key Metrics
Financial Performance over the years – Key Metrics Revenue from Operations- Growth Trends (Rs Mn) FY20 FY21 FY22 FY23 FY24 H1FY25 FY20-24 CAGR: 25% 112% 32% 7,175 6,170 5,678 5,180 5,201 4,270 4,234 3,240 3,420 3,406 2,322 2,396 1,497 932 990 814 74 166 Advance Intermediates Chemicals Total Revenue
Slide 11: Financial Performance over the years – Key Metrics (cont’d)
Financial Performance over the years – Key Metrics (cont’d) EBITDA and EBITDA Margins (%) PAT and PAT Margins (%) 23.5% 1,285 20.2% 1,227 15.9% 18.5% 13.8% 17.1% 833 12.3% 11.5% 808 19.9% 719 1,052 13.5% 17.9% 802 784 540 11.3% 523 410 275 FY20 FY21 FY22 FY23 FY24 H1FY25 FY20 FY21 FY22 FY23 FY24 H1F
Slide 12: Financial Performance over the years - Profit and Loss
Financial Performance over the years - Profit and Loss Particulars (INR mn) FY21 FY22 FY23 FY24 H1 FY25 Revenue from Operations 3,406 5,201 6,167 7,175 4,234 Other Income 14 28 43 75 95 Total Income 3,420 5,229 6,210 7,250 4,329 Cost of materials consumed 1,749 2,823 3,459 4,402 2,481 Changes in inv
Slide 13: Financial Performance over the years - Balance Sheet
Financial Performance over the years - Balance Sheet Assets (INR mn) FY21 FY22 FY23 FY24 H1 FY25 Equity and Liabilities (INR FY21 FY22 FY23 FY24 H1 FY25 mn) Property, plant and 1,422 1,584 1,844 3,229 3,171 equipment Shareholder's equity 1,669 5,223 5,939 6,828 12,118 Right of use assets 184 194 374
Slide 14: Shareholder Information
Shareholder Information Shareholding as on 30th September 2024 Share Information as on 30th September 2024 NSE Ticker AMIORG BSE Ticker 543349 Others Promoters 30.2% 36.0% Market Cap (Rs. Cr) 7,130 Shares Outstanding 4,09,27,511 3M ADTV (Shares)* 2,55,715 3M ADTV (Rs. cr)* 36.93 FII 13.9% Industry S
Slide 15: 2. Company Overview
2. Company Overview Company Overview Our Journey Our Products Strong and Long-term relations with Diversified Customers across Geographies Our Manufacturing Facilities Superior R&D Capabilities Our Founders Our Leadership What makes us different 14
Slide 16: Ami Organics – At a Glance
Ami Organics – At a Glance Business Segments One of the leading Research and Development driven manufacturer of Specialty Chemicals Focused on the development and manufacturing of: • Advanced Pharmaceutical Intermediates Advanced Pharmaceutical Specialty • Specialty Chemicals Intermediates Chemi
Slide 17: The Evolution
The Evolution 2004 2005 2006 Formation of partnership firm in the name of Gujarat Gas Safety Award – developing and Change in constitution from partnership firm to “Ami Organics” implementing effective HSE Management private limited in the name of System “Ami Organics Private Limited” 2016 2015 2011
Slide 18: Business Segments
Business Segments Advanced Pharmaceutical Specialty Chemicals Intermediates ~550 Products invoiced in last 5 years Parabens & Paraben formulations Methyl Salicylate Intermediates across 17+ therapeutic Niche KSMs for cosmetics, finechem and areas agrochem companies ~95% Chronic Therapy f
Slide 19: Strong and Long-term Relations with Diversified Customers across Geographies
Strong and Long-term Relations with Diversified Customers across Geographies Well established long-term relations with domestic customers as well as MNCs 500+ ~45 across large and fast-growing markets Customers Countries Diversified customer base (customer locations) 30+ Long term supply contr
Slide 20: Strong and Long-term relations with Diversified Customers (cont’d)
Strong and Long-term relations with Diversified Customers across Geographies (cont’d) Advanced Generic Pharma Intermediates (Top Clients) Innovators Specialty Chemicals (Top Clients) 19
Slide 21: State-of-the-Art Manufacturing Facilities
State-of-the-Art Manufacturing Facilities 76,891 ~1,100 Total Land Area (sq mtrs) Total Installed Capacity (KL) Sachin, Gujarat Ankleshwar, Gujarat Jhagadia, Gujarat Greater Noida, UP Land Area Installed Capacity Land Area Installed Capacity Land Area Installed Capacity Land Area Installed Capacity
Slide 22: R&D Centric Organization
R&D Centric Organization… R&D Expenditure State-of-the-Art (INR mn) 1 R&D Lab 2 Technology 3 Equipment 65 70 77 141 62 ADL fully supported by analytical • Modern fume hood system 23,681 sq. ft. instruments like: • Autoclave State of art R&D facility at Sachin R&D expenditure as % • LCMASS • High vac
Slide 23: Superior R&D Capabilities (Cont’d)
Superior R&D Capabilities (Cont’d) Our Capabilities in Key Chemistry Etherification Acylation Fluorination Nitration Esterification Bromination Diazotization Hydrogenation Alkylation Amination Chlorination & hydrolysis AMI Organics R&D Centre in Surat 22
Slide 24: Superior R&D Capabilities – Continuous Flow Reactor
Superior R&D Capabilities (Cont’d) Continuous Flow Reactor Continuous flow reactors are more efficient, and sustainable when compared to manufacturing products using traditional reactors. Successfully developed capabilities in Plug Flow, Catalytic fixed-bed flow, Tubular flow kind of reactors
Slide 25: Our Founders
Our Founders Mr. Nareshkumar Patel is founder of the Company He has been associated with the Company since its inception and has extensive experience in the global generic pharma business He is responsible for handling the Chemical Engineering and Product Implementation divisions of the Compan
Slide 26: Our Leadership
Our Leadership Board of Directors Virendra Girikrishna Richa Hetal Dr. Anita Mr. Ram Mohan Mishra Maniar Goyal Gandhi Bandyopadhyay Lokhande Whole – time Non – executive, Non – executive, Non – executive Independent Whole – time Director Independent Director Independent Director Independent Director
Slide 27: What Makes Us Different ?
What Makes Us Different ? Niche Product Portfolio High Entry Diversified Products to Diversified Customer Reputation for Robust Cost with a Strong Market Barriers Support Future Growth Base across Innovative Product Management / Process Share Geographies Launches Supported by Improvements Robust R&D
Slide 28: 3. Advanced Pharma Intermediate
3. Advanced Pharma Intermediate A leading Advanced Intermediate Manufacturer from India Our Business Model Uniqueness of our business model Our Strategy and Outlook Industry Overview 27
Slide 29: Advanced Pharmaceutical Intermediates
Advanced Pharmaceutical Intermediates Historical Business Performance (INR mn) 5,678 17+ 150+ CAGR 25% FY24 Therapeutic Customers 5,678 5,180 Revenue Areas in FY24 (INR mn)) 4,270 3,240 2,322 25+ 15 2 FY20 FY21 FY22 FY23 FY24 Countries Process Patents Manufacturing (Customer locations) (1 patent pub
Slide 30: Our Business Model – Advanced Intermediates for Pharmaceuticals
Our Business Model – Advanced Intermediates for Pharmaceuticals CDMO Contract Manufacturing for big pharma companies ~10% Exclusive long term supply contracts Regulatory market business Supplying NCE molecules to the pharma innovator companies Supplying intermediates to the innovator pharma
Slide 31: Uniqueness of our business model
Uniqueness of our business model 1 2 3 4 5 6 Chronic Therapy Wide Product R&D Presence across Preferred Strong Customer focused Basket Leadership value chain Supplier Base ~95% of the Wider basket of First to market with AMI is present across Our unique business As one of the products ca
Slide 32: Our Strategy – Advanced Pharmaceutical Intermediates
Our Strategy – Advanced Pharmaceutical Intermediates Grow the Innovator business with more focus on CDMO opportunities S T R Commercialise products way ahead of time for drugs going off-patent in the coming years A T Continue to develop innovative products for the global market E G Y Ramp up product
Slide 33: Industry Overview (1/2)
Industry Overview (1/2) Global API Market Global Pharmaceutical Intermediates Market (USD bn) (USD bn) 6.5% CAGR 326 6.2% CAGR 51 6.1% CAGR 238 6.0% CAGR 37 177 28 2018 2023 2028E 2018 2023 2028E Global API Market Split by Therapy 15% 19% CAGR CAGR 27% 25% (2018-23) (2023-28E) 35% 33% Oncology 11% 1
Slide 34: 4. Specialty Chemicals
4. Specialty Chemicals Speciality Chemicals - Overview Our Strategy and Outlook Industry Overview 33
Slide 35: Speciality Chemicals
Speciality Chemicals Historical Business Performance (INR mn) 1,497 3 40+ CAGR 112% FY24 Business Products 1,497 Revenue Segments Specialty Chemicals for various industries e.g. (INR mn) Cosmetics, Finechem, Agrochem, etc. Battery Chemicals 932 990 Semiconductor Chemicals 166 74 340+ 40+ 2 FY2
Slide 36: Our Strategy – Speciality Chemicals
Our Strategy – Speciality Chemicals Development and entry Continue to work on into newer applications improving operational having strong entry efficiencies to deliver barriers better margins Leverage the technology Grow the Battery and capability of Baba Fine Chemicals segment – Chemicals to expand
Slide 37: Industry Overview (2/2)
Industry Overview (2/2) Global Electrolyte Additives and Electrolyte Solutions Market Global Specialty Chemicals Market 20.2 (USD bn) 11.2 (USD bn) 6.5 1,219 3.4 0.8 1.6 937 2018 2023 2028E 785 Electrolyte Additives Electrolyte Solutions Global Photoresist Chemicals and Semiconductor Chemicals Marke
Slide 38: 5. Working towards better tomorrow
5. Working towards better tomorrow 37
Slide 39: ESG Focus – Working towards a Better Tomorrow
ESG Focus – Working towards a Better Tomorrow Environment Social Governance Zero Liquid Discharge based in-house Company’s Sachin facility is SA 8000:2014 50% of the board constitutes of effluent plant at Sachin facility certified independent directors 80% of wastewater recycled The SA8000
Slide 40: Safe Harbor
Safe Harbor The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any
Slide 41: Contact Us
Contact Us For more information please contact: Ami Organics Limited Ekta Srivastava Company Secretary & Compliance Officer cs@amiorganics.com Rahul Thakur Senior Manager – Investor Relations Rahul.thakur@amiorganics.com 40 © 2020 Ami Organics Limited, All Rights Reserved.